The agreement, announced April 9, 2026, builds on a longstanding relationship between the two organisations and is framed around value-based healthcare, clinical quality and joint work on net-zero goals.
Under the deal, Spire will continue to treat Bupa members at its hospitals and clinics, giving them access to eight existing cancer specialist centres across the UK. The partnership also commits both parties to expand oncology and musculoskeletal (MSK) pathways, with plans for five new Bupa cancer specialist centres, five new MSK rapid-access pathway sites and a new gynaecology specialist centre to be added to the network over the life of the agreement.
The announcement comes as Spire positions itself as one of the UK’s largest independent hospital operators, with 38 hospitals and more than 50 clinics, medical centres and consulting rooms across England, Wales and Scotland, treating over a million patients a year.
Nikola Kamel, head of hospital management at Bupa UK Insurance, said the renewed agreement would support faster access and better outcomes for customers.
“Our renewed partnership with Spire Healthcare strengthens our shared commitment to delivering high‑quality, timely care for our customers," Kamel said. "Over the next four years, we’ll keep pushing the boundaries of what great healthcare looks like, making it quicker and simpler for people to get the diagnosis and treatment they need. By working closely together and sharing insight, we can drive meaningful improvements in patient experience and outcomes, while shaping a sustainable future for healthcare.”
The two organisations will share data and work jointly on a value-based healthcare approach, aligning payment more closely to outcomes and quality. They also plan to collaborate across the sector on their net-zero ambitions. Bupa has set a target to become a net-zero business by 2040 across its global operations and value chain, supported by science-based emissions-reduction targets aligned with a 1.5°C pathway.
Peter Corfield, chief commercial officer at Spire Healthcare, said the agreement would deepen the existing relationship with Bupa and broaden the range of services available to customers.
“This four-year strategic agreement will provide Bupa’s UK health insurance customers with access to Spire’s outstanding personalised care at 38 hospitals and over 60 clinics across England, Wales and Scotland, expanding our excellent longstanding partnership with the company," he said.
“We look forward to working with Bupa to develop new cancer, musculoskeletal and gynaecology specialist centres, to offer patients rapid access to diagnostics and clinical expertise to drive the best possible care outcomes.”
Spire currently operates five breast cancer specialist centres in Bristol, Bushey (Watford), Edinburgh, Little Aston (Birmingham) and Southampton, alongside two prostate cancer specialist centres in Bushey and Solihull (Birmingham) and a bowel cancer specialist centre in Portsmouth.
The new agreement will extend that footprint through additional Bupa-branded cancer specialist centres and a dedicated gynaecology hub, reflecting increased demand for rapid access to diagnostics and specialist input in oncology and women’s health.
On the MSK side, Bupa, Spire and Vita Health – which is part of Spire Healthcare Group – have already developed a rapid-access initiative that offers triage within 24 hours and imaging, where required, within three working days. The model is being piloted across six Spire sites and is expected to be rolled out more widely under the new partnership, with five additional MSK rapid-access pathway locations to be added.
The tie-up comes against a backdrop of sustained, PMI-driven demand for private treatment. The number of people with private medical insurance in the UK has been rising in recent years, driven by persistent NHS waiting lists and strong employer interest in health benefits.
Within that market, Bupa is one of the “big four” UK health insurers – alongside AXA Health, Aviva and Vitality – which between them write the vast majority of private medical insurance premium. Bupa’s UK and global businesses have reported growth in customer numbers and revenue, reinforcing its need for long-term provider relationships that can guarantee access and help manage claims costs.
For Spire, private medical insurance remains a key and relatively stable source of income, even as self-pay volumes and NHS-funded work fluctuate. Securing a multi-year agreement with a major payor such as Bupa provides greater visibility over insured volumes and case mix at a time when independent hospital groups are seeking more predictable revenue streams.
As the UK private health market continues to expand on the back of NHS pressures and corporate benefits demand, insurer–provider partnerships such as Bupa and Spire’s four-year deal are likely to play an increasingly important role in how capacity is secured, how care pathways are structured and how risk is shared across the sector.
